While canonical and non-canonical NF-κB signaling are known to have some cross-talk, our mutually adjusted analysis indicates that the effects of p52, a primary contributor to the non-canonical pathway, on ovarian cancer outcomes are independent of canonical NF-κB signaling through p65 expression. Here, NFKB2 is linked to ovarian carcinoma.